{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=101", "query": { "condition": "Lymphoid", "page": 101 }, "page_size": 10 }, "pagination": { "page": 101, "page_size": 10, "total_count": 3083, "total_pages": 309, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=102&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=100&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T18:45:29.354Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02494882", "title": "Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 12, "start_date": "2015-06-29", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-11-13T18:45:29.354Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02494882" }, { "nct_id": "NCT05135650", "title": "Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COVID-19 Infection", "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Sotrovimab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-01-25", "completion_date": "2023-01-10", "has_results": true, "last_update_posted_date": "2025-02-13", "last_synced_at": "2026-11-13T18:45:29.354Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05135650" }, { "nct_id": "NCT05828589", "title": "A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Relapsed Chronic Lymphocytic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Relapsed Follicular Lymphoma", "Relapsed Marginal Zone Lymphoma", "Relapse Diffuse Large B Cell Lymphoma", "Relapsed Small Lymphocytic Lymphoma", "Refractory Follicular Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Small Lymphocytic Lymphoma", "Richter Transformation", "Refractory Diffuse Large B-cell Lymphoma", "Transformed Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "BGB-21447", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2023-06-20", "completion_date": "2026-06-08", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-11-13T18:45:29.354Z", "location_count": 7, "location_summary": "Washington D.C., District of Columbia • Iowa City, Iowa • Waukee, Iowa + 4 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Waukee", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Mineola", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05828589" }, { "nct_id": "NCT03032250", "title": "Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Caregiver", "Malignant Head and Neck Neoplasm", "Paranasal Sinus Squamous Cell Carcinoma", "Salivary Gland Squamous Cell Carcinoma", "Stage I Hypopharyngeal Squamous Cell Carcinoma", "Stage I Laryngeal Squamous Cell Carcinoma", "Stage I Lip and Oral Cavity Squamous Cell Carcinoma", "Stage I Oropharyngeal Squamous Cell Carcinoma", "Stage II Hypopharyngeal Squamous Cell Carcinoma", "Stage II Laryngeal Squamous Cell Carcinoma", "Stage II Lip and Oral Cavity Squamous Cell Carcinoma", "Stage II Oropharyngeal Squamous Cell Carcinoma", "Stage III Hypopharyngeal Squamous Cell Carcinoma", "Stage III Laryngeal Squamous Cell Carcinoma", "Stage III Lip and Oral Cavity Squamous Cell Carcinoma", "Stage III Oropharyngeal Squamous Cell Carcinoma", "Stage IV Hypopharyngeal Squamous Cell Carcinoma", "Stage IV Laryngeal Squamous Cell Carcinoma", "Stage IV Lip and Oral Cavity Squamous Cell Carcinoma", "Stage IV Oropharyngeal Squamous Cell Carcinoma", "Stage IVA Hypopharyngeal Squamous Cell Carcinoma", "Stage IVA Laryngeal Squamous Cell Carcinoma", "Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma", "Stage IVA Oropharyngeal Squamous Cell Carcinoma", "Stage IVB Hypopharyngeal Squamous Cell Carcinoma", "Stage IVB Laryngeal Squamous Cell Carcinoma", "Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma", "Stage IVB Oropharyngeal Squamous Cell Carcinoma", "Stage IVC Hypopharyngeal Squamous Cell Carcinoma", "Stage IVC Laryngeal Squamous Cell Carcinoma", "Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma", "Stage IVC Oropharyngeal Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Lip and Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal SCC", "Recurrent Paranasal Sinus Squamous Cell Carcinoma" ], "interventions": [ { "name": "Communication Intervention", "type": "OTHER" }, { "name": "Watch video", "type": "OTHER" }, { "name": "Module completion of the Prepare to Care kit", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Salivary cortisol collection", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2017-05-15", "completion_date": "2020-04-10", "has_results": true, "last_update_posted_date": "2023-01-09", "last_synced_at": "2026-11-13T18:45:29.354Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03032250" }, { "nct_id": "NCT01154816", "title": "Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatoblastoma", "Previously Treated Childhood Rhabdomyosarcoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Kidney Neoplasm", "Recurrent Childhood Malignant Germ Cell Tumor", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Neuroblastoma", "Recurrent Osteosarcoma" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 118, "start_date": "2011-02", "completion_date": "2019-06-30", "has_results": true, "last_update_posted_date": "2020-05-13", "last_synced_at": "2026-11-13T18:45:29.354Z", "location_count": 97, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01154816" }, { "nct_id": "NCT00609869", "title": "Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphocytic Leukemia", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2007-10", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2015-09-17", "last_synced_at": "2026-11-13T18:45:29.354Z", "location_count": 2, "location_summary": "Lakeland, Florida • Tampa, Florida", "locations": [ { "city": "Lakeland", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00609869" }, { "nct_id": "NCT00005945", "title": "Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "mercaptopurine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "pegaspargase", "type": "DRUG" }, { "name": "thioguanine", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "9 Years", "sex": "ALL", "summary": "1 Year to 9 Years" }, "enrollment_count": 3054, "start_date": "2000-06", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2016-02-23", "last_synced_at": "2026-11-13T18:45:29.354Z", "location_count": 116, "location_summary": "Phoenix, Arizona • Downey, California • Duarte, California + 92 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Downey", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005945" }, { "nct_id": "NCT04296305", "title": "Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Hydromorphone", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2020-09-10", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-11-13T18:45:29.354Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04296305" }, { "nct_id": "NCT00001941", "title": "Anti-Tac for Treatment of Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HTLV-I Infection", "T Cell Leukemia" ], "interventions": [ { "name": "daclizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 34, "start_date": "1999-12", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2012-08-20", "last_synced_at": "2026-11-13T18:45:29.354Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001941" }, { "nct_id": "NCT00462605", "title": "MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Anemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Ringed Sideroblasts", "Refractory Cytopenia With Multilineage Dysplasia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "entinostat", "type": "DRUG" }, { "name": "sargramostim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2007-04", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2017-07-18", "last_synced_at": "2026-11-13T18:45:29.354Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00462605" } ] }